What is IMDX's health score?

Insight Molecular Diagnostics Inc. (IMDX) has a TradeApes health score of 26 out of 100, rated Stressed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is IMDX's estimated fair value?

Based on our 5-year discounted cash flow model, Insight Molecular Diagnostics Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is IMDX undervalued or overvalued?

Our model currently rates IMDX as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for IMDX... Refresh in a moment for the full analysis.

Insight Molecular Diagnostics Inc. (IMDX)

Healthcare Inconclusive inconclusive stressed

$6.47

Updated: 2026-06-04

TradeApes Score

Financial Strength

35 Weak

Operating Trend

28 Stressed

Relative Value

20 Stressed

Capital Allocation

10 Stressed

Risk

35 Weak

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.